About Liraglutide Titration
This information supports the use of the Liraglutide Titration Calculator. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes and chronic weight management. A gradual dose increase, known as titration, is required to minimize gastrointestinal side effects such as nausea, vomiting, and diarrhea. This process allows the body to adapt to the medication, improving tolerability and adherence to treatment.
Calculator Outputs
The calculator generates a clear, date-based dosing schedule based on your inputs. For the selected indication, it provides:
- Weekly Breakdown: A step-by-step schedule showing the dose for each week of titration.
- Start Dates: The specific calendar date to begin each new, higher dose.
- Daily Dose: The amount of liraglutide in milligrams (mg) to be administered daily for that week.
- Pen Setting: The corresponding value to select on the injection pen to deliver the correct daily dose.
How to Use the Calculator
To generate a personalized liraglutide dosing schedule, follow these two simple steps:
- Select Indication for Use: Choose either "Type 2 Diabetes (Victoza®)" or "Chronic Weight Management (Saxenda®)" from the dropdown menu. The titration schedule and target dose differ significantly between these two indications.
- Select Titration Start Date: Use the date picker to choose the day the patient will begin treatment with the initial 0.6 mg dose. The calculator will use this date to map out all subsequent dose increases.
Dosing Overview
Liraglutide administration begins with a low dose that is increased weekly until the maintenance dose is reached. The schedule depends on the brand and indication.
For Type 2 Diabetes (Victoza®):
- Week 1: Start with 0.6 mg injected subcutaneously once daily.
- Week 2: Increase to 1.2 mg once daily.
- Week 3 and beyond: If additional glycemic control is needed, the dose may be increased to the maximum of 1.8 mg once daily.
For Chronic Weight Management (Saxenda®):
- Week 1: Start with 0.6 mg injected subcutaneously once daily.
- Week 2: Increase to 1.2 mg once daily.
- Week 3: Increase to 1.8 mg once daily.
- Week 4: Increase to 2.4 mg once daily.
- Week 5 and beyond: Increase to the maintenance dose of 3.0 mg once daily.
Switching Medications
Switching to liraglutide from another GLP-1 receptor agonist or other antidiabetic agent requires careful consideration by a healthcare professional. There is no single standard protocol, and the decision will depend on the previous medication, patient factors, and clinical judgment. Always consult the full prescribing information and a healthcare provider for guidance on transitioning between therapies.
Missed Dose Instructions
Guidance for a missed dose of liraglutide is as follows:
- If a dose is missed, the patient should skip the missed dose and resume their once-daily schedule with the next planned dose. They should not take an extra dose or increase the next dose to make up for the missed one.
- If more than 3 days have passed since the last dose, the patient should contact their healthcare provider. They may be advised to restart the titration schedule at the 0.6 mg starting dose to mitigate potential gastrointestinal side effects.
Safety Alerts
Boxed Warning: Risk of Thyroid C-cell Tumors
Liraglutide has been shown to cause thyroid C-cell tumors in rodents at clinically relevant exposures. It is not known if it causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Liraglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled on the potential risk and symptoms of thyroid tumors.
Other significant risks include pancreatitis, acute gallbladder disease, hypoglycemia (especially when used with other antidiabetic agents like insulin or sulfonylureas), acute kidney injury, and hypersensitivity reactions. This is not a complete list of risks. Always consult the full prescribing information.
Frequently Asked Questions
The schedules differ because they target different final maintenance doses approved for their specific indications. Victoza® is approved for type 2 diabetes with a maximum dose of 1.8 mg, while Saxenda® is approved for weight management with a higher maintenance dose of 3.0 mg. The longer titration for Saxenda® is necessary to reach this higher dose while maintaining tolerability.
No, you should not increase the dose faster than recommended. The titration schedule is designed specifically to reduce the risk and severity of gastrointestinal side effects. Accelerating the schedule can lead to significant nausea, vomiting, or diarrhea. Always follow the instructions provided by your healthcare provider.
If you experience side effects that are severe or do not go away, contact your healthcare provider immediately. They may recommend staying at the current dose for a longer period before attempting to increase it again, or they may adjust your treatment plan. Do not stop or change your dose without medical advice.
Yes. For both Victoza® and Saxenda® pens, the dose selector is marked in milligrams (mg). The "Pen Setting" value shown in the calculator results corresponds directly to the number you will dial on the pen (e.g., 0.6, 1.2, 1.8).
No. This calculator provides the standard titration schedule based on the FDA-approved prescribing information. It does not account for individual patient factors like renal or hepatic impairment. Dose adjustments may be necessary for certain populations. All treatment decisions must be made by a qualified healthcare professional who can assess your complete medical history.
Victoza® and Saxenda® contain the same active ingredient (liraglutide) but are approved and dosed for different conditions. Victoza® is approved to improve blood sugar in adults with type 2 diabetes and has been shown to have a weight loss benefit, but it is not approved specifically for weight management. Saxenda® is approved for chronic weight management. You should only use the medication prescribed for your specific condition at the dose recommended by your doctor.
Once you reach the target maintenance dose (e.g., 1.8 mg for Victoza® or 3.0 mg for Saxenda®), you will continue to take that dose once daily as long as prescribed by your healthcare provider. Your provider will monitor your progress and determine the appropriate duration of therapy.
The duration a pen lasts depends on the daily dose. Both Victoza® and Saxenda® pens contain 18 mg of liraglutide (3 mL, 6 mg/mL). For example, at a dose of 0.6 mg/day, a pen will last 30 days. At 1.2 mg/day, it will last 15 days. At the 1.8 mg/day Victoza® dose, it will last 10 days. At the 3.0 mg/day Saxenda® dose, it will last 6 days.
References
- Victoza® (liraglutide) injection Prescribing Information. FDA. Revised: 06/2023.
- Saxenda® (liraglutide) injection Prescribing Information. FDA. Revised: 12/2022.
- Victoza® HCP Official Website. Novo Nordisk. Accessed 2023.
- Saxenda® HCP Official Website. Novo Nordisk. Accessed 2023.
- Victoza European public assessment report (EPAR). European Medicines Agency.
